GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
110 hedge funds and large institutions have $320M invested in GenMark Diagnostics, Inc in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 12 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 25
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
4% more funds holding
Funds holding: 106 → 110 (+4)
6% less capital invested
Capital invested by funds: $339M → $320M (-$19.3M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$14.2M |
| 2 |
BlackRock
New York
|
+$2.65M |
| 3 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.23M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
QI
QS Investors
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.45M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$1.67M |
| 4 |
JP Morgan Chase
New York
|
-$1.66M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.3M |
GNMK Hedge Fund Activity: Q3 2019 in Review
110 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2019, worth a combined $320M — down 5.7% from $339M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GNMK positions and 12 closed out — a net gain of 5 holders — while 43 added to existing stakes and 25 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $14.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $22.4M.
- 110 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2019, up from 106 in Q2 2019.
- Funds reported $320M of GenMark Diagnostics, Inc stock for Q3 2019, down 5.7% quarter-over-quarter.
- 17 funds opened new GenMark Diagnostics, Inc positions in Q3 2019 and 12 closed out, a net change of +5 holders.
- The largest GenMark Diagnostics, Inc buyer in Q3 2019 was Morgan Stanley, an estimated $14.2M added.
- The largest GenMark Diagnostics, Inc seller in Q3 2019 was T. Rowe Price Associates, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2019.